London · Delayed Price · Currency is GBP · Price in GBX CVS Group Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and successful rebranding and regulatory compliance initiatives. UK and Australia acquisition pipelines remain robust, supporting a positive outlook.
-
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
Fiscal Year 2025
-
Revenue rose 5.4% to £673.2m and adjusted EBITDA grew 9.4%, with strong cash generation and leverage reduced to 1.18x. Expansion in Australia continues, UK acquisitions are set to resume post-CMA, and medium-term like-for-like growth guidance is 4–8%.
-
Revenue grew 5.4% to £673.2m, with adjusted EBITDA up 9.4% and margin at 20%. Australian expansion continued, and UK operations improved, with strong cash flow and reduced leverage. Confident in medium-term 4%-8% growth, supported by efficiency gains and selective acquisitions.
-
Revenue grew 5.4% to GBP 673.2 million, with Adjusted EBITDA up 9.4% and margin at 20%. Strong cash flow, reduced leverage, and continued expansion in Australia position the group for further growth, despite ongoing CMA investigation and sector headwinds.
-
Revenue rose 6.6% to £341.8m and EBITDA grew 4.5% to £67.4m, with strong expansion in Australia and ongoing UK regulatory uncertainty. The business remains confident in its five-year EBITDA doubling plan and targets a 23% margin by 2027, supported by operational synergies and disciplined capital allocation.
Fiscal Year 2024
-
Revenue grew 9.9% to £647.3m, with adjusted EBITDA up 4.7% to £127.3m, driven by UK and Australian acquisitions. Despite headwinds from a cyber incident and CMA scrutiny, confidence remains in meeting full-year expectations and margin targets.